Monday, April 15, 2013
A voluntary collaboration of EU
member states, patients and industry plans to present recommendations this week
for a framework to assess the value of Orphan drugs that could be used as the
basis for pricing negotiations at the national level.
In principle, the plan seeks to
reduce the health technology assessment burden on smaller EU member states and
make the reimbursement process more predictable for companies, in turn
increasing patient access to Orphan drugs.